FY2025 EPS Estimates for IDYA Lifted by Cantor Fitzgerald

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) – Equities researchers at Cantor Fitzgerald boosted their FY2025 earnings estimates for shares of IDEAYA Biosciences in a note issued to investors on Thursday, November 13th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will post earnings per share of ($1.30) for the year, up from their previous estimate of ($3.00). Cantor Fitzgerald has a “Overweight” rating on the stock. The consensus estimate for IDEAYA Biosciences’ current full-year earnings is ($3.07) per share. Cantor Fitzgerald also issued estimates for IDEAYA Biosciences’ FY2026 earnings at ($3.04) EPS.

IDEAYA Biosciences (NASDAQ:IDYA) last posted its quarterly earnings data on Tuesday, November 4th. The company reported $1.33 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $1.45. The company had revenue of $207.83 million for the quarter, compared to analyst estimates of $59.98 million.

Other equities analysts also recently issued reports about the stock. JPMorgan Chase & Co. raised their target price on shares of IDEAYA Biosciences from $74.00 to $79.00 and gave the company an “overweight” rating in a report on Thursday, October 23rd. JMP Securities initiated coverage on IDEAYA Biosciences in a report on Thursday, September 4th. They set a “market outperform” rating and a $41.00 target price on the stock. Barclays started coverage on shares of IDEAYA Biosciences in a research note on Thursday, September 4th. They issued an “overweight” rating and a $40.00 price target for the company. Stephens reaffirmed an “overweight” rating and issued a $45.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, September 9th. Finally, Royal Bank Of Canada boosted their price objective on IDEAYA Biosciences from $38.00 to $41.00 and gave the company an “outperform” rating in a research report on Tuesday, October 21st. Fourteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, IDEAYA Biosciences presently has an average rating of “Moderate Buy” and a consensus price target of $45.50.

IDEAYA Biosciences Price Performance

Shares of IDYA stock opened at $33.71 on Monday. The firm has a market capitalization of $2.96 billion, a PE ratio of -18.12 and a beta of 0.14. The business’s fifty day moving average price is $28.49 and its 200 day moving average price is $24.39. IDEAYA Biosciences has a 1-year low of $13.45 and a 1-year high of $34.61.

Institutional Trading of IDEAYA Biosciences

A number of hedge funds have recently bought and sold shares of the company. State of New Jersey Common Pension Fund D boosted its position in IDEAYA Biosciences by 11.1% during the second quarter. State of New Jersey Common Pension Fund D now owns 100,827 shares of the company’s stock valued at $2,119,000 after purchasing an additional 10,047 shares during the last quarter. Oppenheimer Asset Management Inc. raised its holdings in IDEAYA Biosciences by 19.3% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 13,787 shares of the company’s stock worth $290,000 after acquiring an additional 2,227 shares during the period. American Century Companies Inc. acquired a new position in shares of IDEAYA Biosciences during the 1st quarter worth about $195,000. Swiss National Bank boosted its position in shares of IDEAYA Biosciences by 0.8% in the first quarter. Swiss National Bank now owns 150,800 shares of the company’s stock valued at $2,470,000 after acquiring an additional 1,200 shares during the period. Finally, Signaturefd LLC grew its position in IDEAYA Biosciences by 58.1% in the 2nd quarter. Signaturefd LLC now owns 4,549 shares of the company’s stock worth $96,000 after purchasing an additional 1,672 shares during the last quarter. 98.29% of the stock is owned by hedge funds and other institutional investors.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.